Excessive Daytime Sleepiness (EDS) Diagnosis Market is segemented By Drug Type (Stimulants, Orexin R...
Market Size in USD Bn
CAGR9.4%
Study Period | 2025-2032 |
Base Year of Estimation | 2024 |
CAGR | 9.4% |
Market Concentration | Medium |
Major Players | Jazz Pharmaceuticals, Takeda Pharmaceutical Company, Harmony Biosciences, Avadel Pharmaceuticals, Bioprojet Pharma and Among Others |
The excessive daytime sleepiness (EDS) diagnosis market is estimated to be valued at USD 7.44 billion in 2025 and is expected to reach USD 13.95 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2032.
The excessive daytime sleepiness (EDS) diagnosis market is growing at a steady rate due to the increasing awareness about sleep disorders and their diagnosis. Rise in lifestyle diseases globally is also leading to increased chances of developing sleep problems.